AGT and diabetic kidney disease: In addition, among patients with diabetic nephropathy, baseline UACR was a strong independent predictor of ESRD in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study and in the Irbesartan in Diabetic Nephropathy Trial (IDNT) 37, 38.